Antiviral applications of Toll-like receptor agonists

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 789-801

  Horscroft, Nigel J ^a   Pryde, David C ^a   Bright, Helen ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Immune modulation; Therapy; TLR; Virus

Indexed keywords

3M 003; AGATOLIMOD; ANA 773; ANA 975; ANTIVIRUS AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CPG 10101; CYTOKINE; GS 9620; IMIQUIMOD; IMO 2125; INTERFERON; ISATORIBINE; N [2 (4 AMINO 2 ETHOXYMETHYL 1H IMIDAZO[4,5 C]QUINOLIN 1 YL) 1,1 DIMETHYLETHYL]METHANESULFONAMIDE; PEGINTERFERON; PF 4171455; PF 4878691; RESIQUIMOD; RIBAVIRIN; SM 276001; SM 324405; SM 360320; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHILL; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; FLU LIKE SYNDROME; GASTROENTERITIS; GENITAL HERPES; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTENSION; IMMUNITY; INNATE IMMUNITY; INTESTINE; LUNG; LYMPHOCYTOPENIA; MEDICAL LITERATURE; MEDICAL RESEARCH; MOLECULE; NAUSEA; NONHUMAN; SIGNAL TRANSDUCTION; VOMITING;

ANTIVIRAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

EID: 84858696578     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr588     Document Type: Article

References (144)

1. Mechnikov I. Nobel Lectures, Physiology or Medicine 1901-1921. Hackensack, NJ: World Scientific Publishing, 1999.
2. Choe J, Kelker MS, Wilson IA. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 2005; 309: 581-5.
3. Diebold SS, Kaisho T, Hemmi H et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-31.
4. Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006; 314: 997-1001.
5. Vollmer J, Weeratna R, Payette P et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251-62.
6. Yang Y, Huang CT, Huang X et al. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5: 508-15.
7. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9: 293-307.
8. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95.
9. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
10. Lemaitre B, Nicolas E, Michaut L et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-83.
11. Hoffmann JA, Reichhart JM. Drosophila innate immunity: an evolutionary perspective. Nat Immunol 2002; 3: 121-6.
12. Chiang C, Beachy PA. Expression of a novel Toll-like gene spans the parasegment boundary and contributes to hedgehog function in the adult eye of Drosophila. Mech Dev 1994; 47: 225-39.
13. Gay NJ, Gangloff M. Structure of Toll-like receptors. Handb Exp Pharmacol 2008: 181-200.
14. Bell JK, Botos I, Hall PR et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA 2005; 102: 10976-80.
15. Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure 2011; 19: 447-59.
16. McGettrick AF, O'Neill LA. Localisation and trafficking of Toll-like receptors: an important mode of regulation. Curr Opin Immunol 2010; 22: 20-7.
17. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004; 279: 19008-17.
18. Nishiya T, Kajita E, Miwa S et al. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biol Chem 2005; 280: 37107-17.
19. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7: 49-56.
20. Horsmans Y, Berg T, Desager J-P et al. Isatoribine, a Toll-like receptor 7 agonist, significantly reduced plasma viral load in a clinical proof-of-concept study in patients with chronic hepatitis C virus infection. Hepatology 2004; 40: 282A-3A.
21. Isogawa M, Robek MD, Furuichi Y et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269-72.
22. Lee J, Wu CC, Lee KJ et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006; 103: 1828-33.
23. Thomas A, Laxton C, Rodman J et al. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 2007; 51: 2969-78.
24. Brikos C, O'Neill LA. Signalling of Toll-like receptors. Handb Exp Pharmacol 2008: 21-50.
25. Seth RB, Sun L, Ea CK et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 2005; 122: 669-82.
26. Li XD, Sun L, Seth RB et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005; 102: 17717-22.
27. Haller O, Kochs G. Interferon-induced Mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002; 3: 710-7.
28. Lenschow DJ, Lai C, Frias-Staheli N et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 2007; 104: 1371-6.
29. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
30. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993; 42: 57-102.
31. Czarniecki M. Small molecule modulators of Toll-like receptors. J Med Chem 2008; 51: 6621-6.
32. Gerster JF, Lindstrom KJ, Miller RL et al. Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J Med Chem 2005; 48: 3481-91.
33. Slade HB, Owens ML, Tomai MA et al. Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs 1998; 7: 437-49.
34. Schon MP, Schon M. The small-molecule immune response modifier imiquimod-its mode of action and clinical use in the treatment of skin cancer. Expert Opin Ther Targets 2006; 10: 69-76.
35. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
36. Strominger NL, Brady R, Gullikson G et al. Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. Brain Res Bull 2001; 55: 445-51.
37. Jones T. Resiquimod 3M. Curr Opin Investig Drugs 2003; 4: 214-8.
38. Pockros PJ, Tong M, Wright T. A phase IIa placebo-controlled, double-blind trial to determine the safety, tolerability, PK/PD of an oral interferon inducer, resiquimod, in chronic HCV. Gastroenterology 2003; 124: A766.
39. Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 1259-68.
40. 3M Innovative Properties Company (Slade HB, Guy CA). Multi-route administration of immune response modifier compounds. WO2006073940. 2006.
41. Shukla NM, Malladi SS, Mutz CA et al. Structure-activity relationships in human Toll-like receptor 7-active imidazoquinoline analogues. J Med Chem 2010; 53: 4450-65.
42. Pfizer. Pfizer to Acquire Coley Pharmaceutical Group. http://www.pfizer.com/news/press_releases/pfizer_press_release_archive.jsp#guid=20071116005284en&source=RSS_2007&page=1 (12 December 2011, date last accessed).
43. Fidock MD, Souberbielle BE, Laxton C et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther 2011; 89: 821-9.
44. Davies SL, Castaner J, Fernandez D. Isatoribine: anti-hepatitis C virus drug TLR7 receptor agonist. Drugs Future 2005; 30: 886-91.
45. Xiang AX, Webber SE, Kerr BM et al. Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids 2007; 26: 635-40.
46. Lee J. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003; 100: 6646-51.
47. Fletcher S, Steffy K, Averett D. Masked oral prodrugs of Toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr Opin Investig Drugs 2006; 7: 702-8.
48. Averett D. ANA975, an orally administered TLR7 immunotherapeutic under evaluation for treatment of chronic HCV infection. In: The Third Annual Viral Hepatitis in Drug Discovery & Development World Summit, Boston, MA, 2007.
49. Anadys Pharmaceuticals Inc. (Averett D). Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus. WO-2005025583. 2005.
50. Anadys. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights. http://www.anadyspharma.com/pr_pdfs/q3%20financial%20results%20final%2011.8.10.pdf (12 December 2011, date last accessed).
51. Ishii KJ, Gursel I, Gursel M et al. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr Opin Mol Ther 2004; 6: 166-74.
52. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-84.
53. Paul S. Technology evaluation: CpG-7909, Coley. Curr Opin Mol Ther 2003; 5: 553-9.
54. Hirsh V, Paz-Ares L, Boyer M et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2667-74.
55. Vicari AP, Schmalbach T, Lekstrom-Himes J et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic Toll-like receptor 9 agonist. Antivir Ther 2007; 12: 741-51.
56. Hirota K, Kazaoka K, Niimoto I et al. Discovery of 8-hydroxyadenines as a novel type of interferon inducer. J Med Chem 2002; 45: 5419-22.
57. Isobe Y, Tobe M, Ogita H et al. Synthesis and structure-activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. Bioorg Med Chem 2003; 11: 3641-7.
58. Hirota K, Kazaoka K, Niimoto I et al. Efficient synthesis of 2,9-disubstituted 8-hydroxyadenine derivatives. Org Biomol Chem 2003; 1: 1354-65.
59. Kurimoto A, Ogino T, Ichii S et al. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorg Med Chem 2004; 12: 1091-9.
60. Isobe Y, Kurimoto A, Tobe M et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem 2006; 49: 2088-95.
61. AstraZeneca (Abbott P, Bonnert RV, Brough S et al.). Purine derivatives for the treatment of viral or allergic diseases and cancers. WO-2007034173. 2007.
62. Kurimoto A, Hashimoto K, Nakamura T et al. Synthesis and biological evaluation of 8-oxoadenine derivatives as Toll-like receptor 7 agonists introducing the antedrug concept. J Med Chem 2010; 53: 2964-72.
63. Weterings JJ, Khan S, Drijfhout JW et al. Synthesis of modified and hybrid protein derived biopolymers. Adv Exp Med Biol 2009; 611: 141-2.
64. Pryde DC, Tran T-D, Jones P et al. The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection. Med Chem Commun 2011; 2: 185-9.
65. Tumas D, Zheng X, Lu B et al. Preclinical characterization of GS-9620, a potent and selective oral TLR7 agonist. In: Abstracts of the Forty-sixth Annual Meeting of the European Association for the Study of the Liver, Berlin, 2011. Abstract 1007.
66. Menne S, Tennant B, Liu K et al. Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. In: Abstracts of the Forty-sixth Annual Meeting of the European Association for the Study of the Liver, Berlin, 2011. Abstract 992.
67. Lanford RE, Guerra B, Chavez DC et al. Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees. In: Abstracts of the Forty-sixth Annual Meeting of the European Association for the Study of the Liver, Berlin, 2011. Abstract 384.
68. Lopatin U, Wolfgang G, Kimberlin R et al. A phase-I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single escalating oral doses of GS-9620 in healthy subjects. In: Abstracts of the Forty-sixth Annual Meeting of the European Association for the Study of the Liver, Berlin, 2011. Abstract 614.
69. Kandimalla ER, Bhagat L, Zhu F-g et al. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci USA 2003; 100: 14303-8.
70. Kandimalla ER, Bhagat L, Li Y et al. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proc Natl Acad Sci USA 2005; 102: 6925-30.
71. Putta MR, Yu D, Bhagat L et al. Impact of nature and length of linker incorporated in agonists on Toll-like receptor 9-mediated immune responses. J Med Chem 2010; 53: 3730-8.
72. Switaj T, Lasek W. Technology evaluation: HYB-2055, hybridon. Curr Opin Mol Ther 2005; 7: 376-83.
73. Idera Pharmaceuticals. Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients at EASL 2011. http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1545377&highlight= (12 December 2011, date last accessed).
74. Idera Pharmaceuticals. Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients. http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1553632&highlight= (12 December 2011, date last accessed).
75. Lan T, Dai M, Wang D et al. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. J Med Chem 2009; 52: 6871-9.
76. Wong JP, Christopher ME, Viswanathan S et al. Antiviral role of Toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr Pharm Des 2009; 15: 1269-74.
77. Boukhvalova MS, Sotomayor TB, Point RC et al. Activation of interferon response through Toll-like receptor 3 impacts viral pathogenesis and pulmonary Toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model. J Interferon Cytokine Res 2010; 30: 229-42.
78. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443-9.
79. Rosenfeld MR, Chamberlain MC, Grossman SA et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 2010; 12: 1071-7.
80. Hammerbeck DM, Burleson GR, Schuller CJ et al. Administration of a dual Toll-like receptor 7 and Toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res 2007; 73: 1-11.
81. Levy O, Suter EE, Miller RL et al. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006; 108: 1284-90.
82. Corixa Corporation (Persing DH, Crane RT, Elliot GT et al.). Prophylactic and therapeutic treatment of infectious and other diseases with monoand disaccharide-based compounds. US2003105032. 2003.
83. Alderson MR, McGowan P, Baldridge JR et al. TLR4 agonists as immunomodulatory agents. J Endotoxin Res 2006; 12: 313-9.
84. Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005; 79: 2910-9.
85. Wong JP, Christopher ME, Salazar AM et al. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 2007; 25: 3175-8.
86. Cluff CW, Baldridge JR, Stoever AG et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 2005; 73: 3044-52.
87. Wu CCN, Hayashi T, Takabayashi K et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci USA 2007; 104: 3990-5.
88. Eisai Corporation (Fang FG, Foy JE, Hawkins L et al.). Compounds for preparing immunological adjuvant. WO2007005583. 2007.
89. Eisai Corporation (Rossignol DP, Ishizaka ST, Hawkins LD et al.). Composition and methods for cancer immunotherapy. WO2006116423. 2006.
90. Baldridge J, Myers K, Johnson D et al. Monophosphoryl lipid A and synthetic lipid A mimetics as TLR4-based adjuvants and immunomodulators. In: Vaccine Adjuvants: Methods and Protocols. Secaucus, NJ: Springer, 2006; 235-55.
91. SmithKline Beechams Biologicals (Boon T, Silla S, Uyttenhove C). Adjuvant compositions for vaccines. US6375945. 2002.
92. Reitz AB, Goodman MG, Pope BL et al. Small-molecule immunostimulants. Synthesis and activity of 7,8-disubstituted guanosines and structurally related compounds. J Med Chem 1994; 37: 3561-78.
93. Cistem Biotechnologies (Fritz J, Mattner F, Zauner W et al.). Vaccine composition. WO2002032451. 2002.
94. Intercell (Buschle M, Habel A, Fritz J et al.). Improved vaccines. WO2004084938. 2004.
95. Sung JJ, Lik-Yuen H. HBV-ISS (Dynavax). Curr Opin Mol Ther 2006; 8: 150-5.
96. Dynavax Technologies Corporation (Raz E, Roman M, Dina D). Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof. US06589940. 2003.
97. Dynavax Technologies Corporation (Van Nest G, Tuck S, Fearon KL et al.). Immunomodulatory compositions, methods of making, and methods of use thereof. WO2004014322. 2004.
98. Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 2011; 10: 417-27.
99. Friedberg JW, Kelly JL, Neuberg D et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009; 146: 282-91.
100. Dynavax. Dynavax Establishes Collaboration for TLR-9 Agonists for Asthma and COPD With AstraZeneca. http://investors.dynavax.com/releasedetail.cfm?ReleaseID=231029 (12 December 2011, date last accessed).
101. Foy E, Li K, Wang C et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-8
102. Ferreon JC, Ferreon AC, Li K et al. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol Chem 2005; 280: 20483-92.
103. Foy E, Li K, Sumpter R Jr et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 2005; 102: 2986-91.
104. Johnson CL, Owen DM, Gale M Jr. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J Biol Chem 2007; 282: 10792-803.
105. Fowell AJ, Nash KL. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010; 27: 512-22.
106. Joo CH, Shin YC, Gack M et al. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol 2007; 81: 8282-92.
107. Bowie A, Kiss-Toth E, Symons JA et al. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc Natl Acad Sci USA 2000; 97: 10162-7.
108. DiPerna G, Stack J, Bowie AG et al. Poxvirus protein N1L targets the I-κB kinase complex, inhibits signaling to NF-κB by the tumor necrosis factor superfamily of receptors, and inhibits NF-κB and IRF3 signaling by Toll-like receptors. J Biol Chem 2004; 279: 36570-8.
109. Andrejeva J, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter. Proc Natl Acad Sci USA 2004; 101: 17264-9.
110. Childs K, Stock N, Ross C et al. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 2007; 359: 190-200.
111. Fernandez-Sesma A, Marukian S, Ebersole BJ et al. Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol 2006; 80: 6295-304.
112. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-28.
113. Gunzer M, Riemann H, Basoglu Y et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 2005; 106: 2424-32.
114. Lewis DE, Gilbert BE, Knight V. Influenza virus infection induces functional alterations in peripheral blood lymphocytes. J Immunol 1986; 137: 3777-81.
115. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10: 811-3.
116. Boule MW, Broughton C, Mackay F et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199: 1631-40.
117. Christensen SR, Kashgarian M, Alexopoulou L et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202: 321-31.
118. Deng GM, Nilsson IM, Verdrengh M et al. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 1999; 5: 702-5.
119. Zipris D, Lien E, Nair A et al. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 2007; 178: 693-701.
120. Patole PS, Grone HJ, Segerer S et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005; 16: 1326-38.
121. Conti B, Davis CN, Behrens MM et al. Toll-like receptors as pharmacological targets. In: O'Neill LA, Brint E, eds. Toll-like Receptors in Inflammation. Basel: Birkhauser Verlag AG, 2006; 223-40.
122. Hoffman ES, Smith RE, Renaud RC Jr. From the analyst's couch: TLR-targeted therapeutics. Nat Rev Drug Discov 2005; 4: 879-80.
123. Kanzler H, Barrat FJ, Hessel EM et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-9.
124. Bieback K, Lien E, Klagge IM et al. Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J Virol 2002; 76: 8729-36.
125. Alexopoulou L, Holt AC, Medzhitov R et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413: 732-8.
126. Matsumoto M, Kikkawa S, Kohase M et al. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 2002; 293: 1364-9.
127. Le Goffic R, Pothlichet J, Vitour D et al. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 2007; 178: 3368-72.
128. Guillot L, Le Goffic R, Bloch S et al. Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005; 280: 5571-80.
129. Ehl S, Bischoff R, Ostler T et al. The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus. Eur J Immunol 2004; 34: 1146-53.
130. Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401.
131. Monick MM, Yarovinsky TO, Powers LS et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003; 278: 53035-44.
132. Georgel P, Jiang Z, Kunz S et al. Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 2007; 362: 304-13.
133. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004; 303: 1526-9.
134. Triantafilou K, Vakakis E, Orthopoulos G et al. TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1. Eur J Immunol 2005; 35: 2416-23.
135. Barchet W, Krug A, Cella M et al. Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur J Immunol 2005; 35: 236-42.
136. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101: 5598-603.
137. Hochrein H, Schlatter B, O'Keeffe M et al. Herpes simplex virus type-1 induces IFN-α production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci USA 2004; 101: 11416-21.
138. Lund J, Sato A, Akira S et al. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513-20.
139. Wuest T, Austin BA, Uematsu S et al. Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10. J Neuroimmunol 2006; 179: 46-52.
140. Chuang TH, Lee J, Kline L et al. Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 2002; 71: 538-44.
141. Hornung V, Ellegast J, Kim S et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314: 994-7.
142. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-7.
143. Plumet S, Herschke F, Bourhis JM et al. Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. PLoS ONE 2007; 2: e279.
144. Vidal D. Topical imiquimod: mechanism of action and clinical applications. Mini Rev Med Chem 2006; 6: 499-503.